Department of Neurosciences and Behavior, Faculty of Medicine of Ribeirão Preto, University of São Paulo, São Paulo, Brazil.
National Institute for Translational Medicine (INCT-TM; CNPq), São Paulo, Brazil.
Front Immunol. 2018 Sep 21;9:2009. doi: 10.3389/fimmu.2018.02009. eCollection 2018.
Among the many cannabinoids in the cannabis plant, cannabidiol (CBD) is a compound that does not produce the typical subjective effects of marijuana. The aim of the present review is to describe the main advances in the development of the experimental and clinical use of cannabidiol CBD in neuropsychiatry. A non-systematic search was performed for studies dealing with therapeutic applications of CBD, especially performed by Brazilian researchers. CBD was shown to have anxiolytic, antipsychotic and neuroprotective properties. In addition, basic and clinical investigations on the effects of CBD have been carried out in the context of many other health conditions, including its potential use in epilepsy, substance abuse and dependence, schizophrenia, social phobia, post-traumatic stress, depression, bipolar disorder, sleep disorders, and Parkinson. CBD is an useful and promising molecule that may help patients with a number of clinical conditions. Controlled clinical trials with different neuropsychiatric populations that are currently under investigation should bring important answers in the near future and support the translation of research findings to clinical settings.
在大麻植物中发现的多种大麻素中，大麻二酚（CBD）是一种不会产生大麻典型主观效应的化合物。本综述旨在描述 CBD 在神经精神疾病方面的实验和临床应用的主要进展。对涉及 CBD 治疗应用的研究进行了非系统性检索，尤其是由巴西研究人员进行的研究。研究表明 CBD 具有抗焦虑、抗精神病和神经保护作用。此外，还在许多其他健康状况的背景下对 CBD 的影响进行了基础和临床研究，包括其在癫痫、药物滥用和依赖、精神分裂症、社交恐惧症、创伤后应激、抑郁、双相情感障碍、睡眠障碍和帕金森病等方面的潜在用途。CBD 是一种有用且有前途的分子，可能有助于许多临床疾病的患者。目前正在进行的针对不同神经精神疾病人群的对照临床试验将在不久的将来带来重要的答案，并支持将研究结果转化为临床环境。
